Home · Health · Nov 10 archive

FDA Mandates GLP-1 Drugs to Warn of Rare Eye Condition

· Confirmed

Health Desk

In Short: The FDA now requires makers of GLP-1 drugs to add a warning about a rare eye condition that can cause sudden blindness.

FDA orders new warning on Ozempic, Wegovy, other GLP-1 drugs over rare eye condition
YouTube — ABC News

FDA orders new warning on Ozempic, Wegovy, other GLP-1 drugs over rare eye condition. ABC News

The U.S. Food and Drug Administration (FDA) announced on Monday that it will require makers of GLP-1 receptor agonist drugs, such as Ozempic, Wegovy, and Zepbound, to add a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) to their drug labels.

According to the FDA, the condition is rare, occurring in between two and 10 people in 100,000 in the general population, but the risk increases to about six in 100,000 for those taking GLP-1 drugs.

In a meta-analysis of 126 clinical trials, including a total of 134,253 participants, the FDA identified 15 probable NAION cases: 10 in patients taking a GLP-1 drug, five in patients who received a placebo, and none in patients on non-GLP-1 drugs.

The FDA's decision comes after an intensive review of studies and clinical trials, which showed a potential increased risk of NAION associated with the use of GLP-1 drugs.

Experts say the condition is known as non-arteritic anterior ischemic optic neuropathy, or NAION, and it comes out of nowhere, significantly impacting patients' lives.

The FDA emphasized that the condition is rare but serious, and that patients should not view GLP-1 drugs as merely weight loss aids but as medications for significant medical conditions.

Hundreds of lawsuits across the country have been filed by patients who claim GLP-1s caused them to go blind, though scientific evidence so far does not prove a cause-and-effect relationship between GLP-1s and NAION.

According to AARP, in 2025, an estimated 63 million Americans will be caring for adults or children with a medical condition or disability, highlighting the importance of such warnings for caregivers and patients alike.

What this adds

The FDA's meta-analysis of 126 clinical trials identified 15 probable NAION events, with 10 occurring in patients taking GLP-1 medications.

Out of 104 state prisons, 38 are fully air-conditioned, highlighting the broader context of health and safety concerns in various sectors.

People with ADHD had a 70 percent higher hazard of death from any cause than people without the condition, underscoring the importance of addressing health risks comprehensively.

Background

The FDA has required drugmakers to add warnings about a potential increased risk of NAION, a rare eye condition, to the labels of all GLP-1 drugs.

The U.S. Food and Drug Administration (FDA) has mandated that makers of GLP-1 receptor agonist drugs, such as Ozempic, Wegovy, and Zepbound, must now include a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) on their drug labels.

What's confirmed

What's still developing

Sources